2013 Symposium

The OMOP-IMEDS 2013 Symposium sponsored by the Reagan-Udall Foundation for the FDA, had over 200 people in attendance, including representation from FDA, academic, pharmaceutical and research organizations. If you missed this year’s symposium or want to hear it again, click below on any of the presentations and download the audio/slides. Some files may take a few seconds to download.

I'm in the audience at OMOP-watching talks as they are told-Searching through the SQL-Just to find the perfect code
Must be a signal in these data-Have no doubt deep in my mind-With the OMOP toolbox-I'll be able to find.

November 5 - 6, 2013 Symposium Materials

  • Symposium Agenda
  • Symposium Bios
  • Demonstration Descriptions
  • Poster Listing
  • References


    2013 Symposium Slides and Audio
    Day 1, November 5, 2013
    The first link will download for you the slides in Adobe format. The second link will start the slides/audio presentation.
  • Exploring the OMOP Common Data Model; Patrick Ryan, PhD; Director, Epidemiology, Janssen Research and Development
  • CDM slides with audio (Includes introduction to the symposium by Paul Stang, PhD, Vice-President, Global Epidemiology, Janssen Research and Development)

  • Exploiting the OMOP Vocabulary Model for Analysis; Christian Reich, MD, PhD; Global Head of Informatics, AstraZeneca PLC
  • Vocabulary slides with audio

  • Implementing Study Designs in the OMOP Environment; David Madigan, PhD; Executive Vice President for Arts and Sciences and Dean of the Faculty of Arts and Sciences, Columbia University
  • Study Designs slides with audio

    Day 2, November 6, 2013
    The first link will download for you the slides in Adobe format. The second link will start the slides/audio presentation.

  • Desideratum for Evidence Based Epidemiology; J. Marc Overhage, MD, PhD; Chief Medical Informatics Officer, Siemens Health Services
  • Evidence base epidemiology slides with audio (Includes introduction to the symposium by Paul Stang, PhD, Vice-President, Global Epidemiology, Janssen Research and Development)

  • Replication of the OMOP Experiment in Europe; Martijn Schuemie PhD; Associate Director, Epidemiology, Janssen Research and Development
  • Replication of the OMOP slides with audio (Includes announcements of poster awards)

  • Beyond Crude Cohort Designs: Large-Scale Adjustment Approaches for Effect Estimation; Marc Suchard, MD, PhD; Professor, University of California, Los Angeles
  • Beyond crude cohort designs slides with audio

  • Impact of Combining Estimates on Performance; David Madigan, PhD; Executive Vice President for Arts and Sciences and Dean of the Faculty of Arts and Sciences, Columbia University
  • Impact of Combining Estimates slides with audio

  • OMOP's Vision of Risk Identification; Patrick Ryan, PhD; Director, Epidemiology, Janssen Research and Development
  • OMOP's Vision of Risk Identification slides with audio

  • Closing Comments; Richard Moscicki, MD; Deputy Center Director for Science Operations, Center for Drug Evaluation and Research, FDA; and Mark McClellan, MD, PhD; Senior Fellow and Director of the Health Care Innovation and Value Initiative, Brookings Institution; Board Member, Reagan-Udall Foundation for the FDA



    2013 Posters
  • AttachmentSize
    01_MapReduce_ETL_Ephir.png1.04 MB
    02_Harpaz_New Interfaces to Established Methods.pdf430.86 KB
    03_Gouripeddi_OpenFurther_OMOP Datasets.pdf606.92 KB
    04_Knoll_OMOP CDM for Clincial Trial Feasibility Assessment.pdf499.16 KB
    05_Meeker_System and User Interface.pdf835.98 KB
    06_Huser_NIH_IDR comparison and desiderata.pdf424.06 KB
    07_Rocca_FDA_Harminization of the OMOP CDM with BRIDG Model.pdf906.42 KB
    08_Jones_Using an Online DB Resource to Characterize HC Data Linkage.pdf186.92 KB
    09_Fraeman_Evidera_Creating Modified OMOP Drug Eras.pdf435.64 KB
    10_Karr_Effects of Method Parameters.pdf8.31 MB
    11_Obenchain_NISS_Observational CER.pdf871.84 KB
    12_Wu_Sanofi_Evaluation of Analytical Method Performance Using SCCS.pdf1009.68 KB
    13_Gruber_Impact of OSIM2.pdf1.23 MB
    14_Zhou_Leverging THIN Data in the OMOP CDM.pdf929.38 KB
    15_Boyce-GeriOMOP-OSIM-MDS-2013-CORRECTED.pdf416.38 KB
    16_Hosokawa_Operationalizing Asthma Analytic Plan Using OMOP CDM.pdf1.19 MB
    17_Kawabata_An Examination of OMOP CDM Vocabulary.pdf245.52 KB
    18_Voss_Quality Checks and Measures into a CDM.pdf383.06 KB
    19_Zhang_OMOP CDM conversion into AsPEN for SCAN project.pdf649.08 KB
    20_Murray_Premier Alliance Data into the OMOP CDM.pdf1.12 MB
    21_Makadia_Premier DB to the OMOP CDM.pdf362.04 KB
    22_Yamashita_Mapping Medicaid and Medicare claims.pdf427.18 KB
    23_Matcho_CPRD to the OMOP CDM.pdf290.44 KB
    26_Juneau_Graphically Examining Potential Hetergeneous Tx Effects.pdf1.1 MB
    27_Esposito_IPF cases in an electronic insurance claims db.pdf180.52 KB
    28_West_Multistate Markov Modeling.pdf1.04 MB
    29_Ofner_Regenstrief_Sensitivity Analysis of Methods for AMI.pdf231.17 KB
    30_Li_Regenstrief_Calibrating Strength of Association of Drug-Outcome Pairs.pdf668.23 KB
    31_Shaddox_Extending Bayesian.pdf247.36 KB
    32_Zhu_Switching in Medication Adherence.pdf316.14 KB
    33_Lo_Mining ADR from EHR.pdf151.92 KB
    34_Weinstein_ALI seasonality.pdf948.77 KB
    35_Shahn_Predicting Strokes.pdf545.22 KB